Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers

Abstract

No relevant drug-drug interaction was observed, and pharmacokinetic results suggest that no dose adjustments for either drug are necessary when empagliflozin and simvastatin are co-administered. Empagliflozin was well tolerated when administered alone or in combination with simvastatin.

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

“…29 Dapagliflozin is also metabolized mainly in the liver and kidneys by UGT1A9, 28 and a lack of clinically meaningful DDI was reported when dapagliflozin was coadministered with either sitagliptin, metformin, glimepiride, or simvastatin. 26,27 Similarly, no relevant DDIs were observed when empagliflozin was coadministered with simvastatin, 30 metformin, 31 or sitagliptin. 32 In summary, the lack of PK interactions demonstrates that ertugliflozin can be administered with sitagliptin, metformin, simvastatin, or glimepiride without any need for dose adjustments.…”

“…Dapagliflozin is also metabolized mainly in the liver and kidneys by UGT1A9, and a lack of clinically meaningful DDI was reported when dapagliflozin was coadministered with either sitagliptin, metformin, glimepiride, or simvastatin . Similarly, no relevant DDIs were observed when empagliflozin was coadministered with simvastatin, metformin, or sitagliptin …”

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

“…A series of randomized, open-label, crossover studies in healthy volunteers indicated that there were no clinically relevant interactions between empagliflozin and medications that are commonly prescribed for patients with diabetes (verapamil, ramipril, digoxin, warfarin, gemfibrozil, and simvastatin), nor commonly used contraceptives, 20 and that food had no clinically relevant effect on exposure to empagliflozin. 21-25 A single-dose study in patients with mild, moderate, or severe hepatic impairment demonstrated that no dose adjustment was needed in these groups. 26…”

Interacciones Farmacológicas De Estatinas Con Agentes Antidiabéticos No Insulínicos

“…Empagliflozina no tuvo efectos en el AUC de simvastatina ácida, su metabolito activo. Los autores concluyeron que no existen interacciones relevantes entre ambas drogas y que no se requiere ajuste en la dosis de estos fármacos al ser co-administrados 22 . Agonistas del receptor del péptido simil glucagón tipo 1 (aGLP-1) Liraglutide, como otros agonistas GLP-1, retrasa el vaciado gástrico.…”

“…Con respecto a exenatide, esta droga ha sido estudiada con lovastatina en sujetos sanos. No se han detectado cambios significativos y no se recomienda ajuste de dosis en estas combinaciones [18][19][20][21][22][23][24] .…”